Reimbursement Review Reports

The latest Reimbursement Review reports are posted to this page. Our Reimbursement Reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.

For each drug, plasma product, or cell and gene therapy reviewed in the Drug Reimbursement Review process, there is an opportunity for patient groups and clinician groups to provide input and feedback. See Reimbursement Review Open Calls for Input and Feedback.

Brand Name Sort descending Generic Name Therapeutic Area Recommendation Type Project Status Date Submission Received Date Recommendation Issued
Nesina Alogliptin Diabetes mellitus, type 2 Do not list Complete
Neulasta Pegfilgrastim Neutropenia List with clinical criteria and/or conditions Complete
Neupro Rotigotine Parkinson's disease Do not list Complete
Neupro Rotigotine Parkinson’s disease List with clinical criteria and/or conditions Complete
Nexavar Sorafenib Metastatic Progressive Differentiated Thyroid Carcinoma (DTC) Do not reimburse Complete
Nexavar Sorafenib tablets Cancer, Renal cell carcinoma Do not list Complete
Nexplanon etonogestrel Prevention of pregnancy Reimburse with clinical criteria and/or conditions Complete
Nexviazyme avalglucosidase alfa Pompe disease Reimburse with clinical criteria and/or conditions Complete
Ngenla somatrogon Growth hormone deficiency Reimburse with clinical criteria and/or conditions Complete
Ninlaro Ixazomib Multiple Myeloma (2nd-beyond) Do not reimburse Complete